These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2684681)

  • 1. Oral iron chelators: prospects for future development.
    Porter J
    Eur J Haematol; 1989 Oct; 43(4):271-85. PubMed ID: 2684681
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of orally active iron chelators.
    Hider RC; Choudhury R; Rai BL; Dehkordi LS; Singh S
    Acta Haematol; 1996; 95(1):6-12. PubMed ID: 8604587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral iron chelators: new opportunities and new dilemmas.
    Hershko C
    Haematologica; 2006 Oct; 91(10):1307-12. PubMed ID: 17018378
    [No Abstract]   [Full Text] [Related]  

  • 4. The design of orally active iron chelators.
    Hider RC; Zhou T
    Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelators for clinical use.
    Tilbrook GS; Hider RC
    Met Ions Biol Syst; 1998; 35():691-730. PubMed ID: 9444773
    [No Abstract]   [Full Text] [Related]  

  • 6. Contrast-enhanced magnetic resonance imaging of the liver.
    Van Beers B
    J Belge Radiol; 1997 Dec; 80(6):322. PubMed ID: 9479919
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo testing of oral iron chelators intended for clinical use.
    Kontoghiorghes G
    Blood; 1991 Jul; 78(2):535-7. PubMed ID: 2070091
    [No Abstract]   [Full Text] [Related]  

  • 8. Deferasirox Novartis.
    Barton JC
    Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential protection from toxicity by oral iron chelators.
    Hider RC
    Toxicol Lett; 1995 Dec; 82-83():961-7. PubMed ID: 8597168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of iron by extracellular iron reductases: implications for microbial iron acquisition.
    Cowart RE
    Arch Biochem Biophys; 2002 Apr; 400(2):273-81. PubMed ID: 12054438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral iron chelator L1 on iron absorption in man.
    Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
    Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral iron chelators.
    Bhattacharyya A
    Indian Pediatr; 1996 Apr; 33(4):342-4. PubMed ID: 8772917
    [No Abstract]   [Full Text] [Related]  

  • 13. Membrane permeability of redox active metal chelators: an important element in reducing hydroxyl radical induced NAD+ depletion in neuronal cells.
    Jayasena T; Grant RS; Keerthisinghe N; Solaja I; Smythe GA
    Neurosci Res; 2007 Mar; 57(3):454-61. PubMed ID: 17210195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral iron chelators.
    Lancet; 1989 Oct; 2(8670):1016-7. PubMed ID: 2572743
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron chelation, quo vadis?
    Nick H
    Curr Opin Chem Biol; 2007 Aug; 11(4):419-23. PubMed ID: 17644021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative radical scavenging ability of bidentate iron (III) chelators.
    Kayyali R; Pannala AS; Khodr H; Hider RC
    Biochem Pharmacol; 1998 Apr; 55(8):1327-32. PubMed ID: 9719489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
    J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral iron chelators.
    Cappellini MD; Pattoneri P
    Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of apolactoferrin with a very low iron saturation.
    Feng M; van der Does L; Bantjes A
    J Dairy Sci; 1995 Nov; 78(11):2352-7. PubMed ID: 8747325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
    Alta EC; Goswami D; Machini MT; Silvestre DM; Nomura CS; Espósito BP
    Biometals; 2014 Dec; 27(6):1351-60. PubMed ID: 25265871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.